148 related articles for article (PubMed ID: 29072678)
1. Specific detection of soluble EphA2 fragments in blood as a new biomarker for pancreatic cancer.
Koshikawa N; Minegishi T; Kiyokawa H; Seiki M
Cell Death Dis; 2017 Oct; 8(10):e3134. PubMed ID: 29072678
[TBL] [Abstract][Full Text] [Related]
2. Serum Exo-EphA2 as a Potential Diagnostic Biomarker for Pancreatic Cancer.
Wei Q; Zhang J; Li Z; Wei L; Ren L
Pancreas; 2020 Oct; 49(9):1213-1219. PubMed ID: 32898008
[TBL] [Abstract][Full Text] [Related]
3. Activated EphA2 Processing by MT1-MMP Is Involved in Malignant Transformation of Ovarian Tumours
Takahashi Y; Hamasaki M; Aoki M; Koga K; Koshikawa N; Miyamoto S; Nabeshima K
Anticancer Res; 2018 Jul; 38(7):4257-4266. PubMed ID: 29970559
[TBL] [Abstract][Full Text] [Related]
4. EphA2‑enriched exosomes promote cell migration and are a potential diagnostic serum marker in pancreatic cancer.
Wei Q; Wei L; Zhang J; Li Z; Feng H; Ren L
Mol Med Rep; 2020 Oct; 22(4):2941-2947. PubMed ID: 32945400
[TBL] [Abstract][Full Text] [Related]
5. Identification of Proteolytic Cleavage Sites of EphA2 by Membrane Type 1 Matrix Metalloproteinase on the Surface of Cancer Cells.
Kikuchi K; Kozuka-Hata H; Oyama M; Seiki M; Koshikawa N
Methods Mol Biol; 2018; 1731():29-37. PubMed ID: 29318540
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical demonstration of EphA2 processing by MT1-MMP in invasive cutaneous squamous cell carcinoma.
Tatsukawa R; Koga K; Aoki M; Koshikawa N; Imafuku S; Nakayama J; Nabeshima K
Virchows Arch; 2016 Jul; 469(1):25-34. PubMed ID: 27056569
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of anti-erythropoietin producing Hepatocellular receptor Type-A2 antibody in pancreatic cancer treatment.
Chang FL; Tsai KC; Lin TY; Chiang CW; Pan SL; Lee YC
Heliyon; 2023 Nov; 9(11):e21774. PubMed ID: 38034633
[TBL] [Abstract][Full Text] [Related]
8. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
9. Optimization of stereospecific targeting technique for selective production of monoclonal antibodies against native ephrin type-A receptor 2.
Yamasaki Y; Miyamae C; Isozaki Y; Ichikawa K; Kaneko Y; Oda Y; Murayama T; Sakurai T; Tamai K; Tsumoto K; Tomita M
J Immunol Methods; 2020; 484-485():112813. PubMed ID: 32592774
[TBL] [Abstract][Full Text] [Related]
10. Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein.
Koshikawa N; Hoshino D; Taniguchi H; Minegishi T; Tomari T; Nam SO; Aoki M; Sueta T; Nakagawa T; Miyamoto S; Nabeshima K; Weaver AM; Seiki M
Cancer Res; 2015 Aug; 75(16):3327-39. PubMed ID: 26130649
[TBL] [Abstract][Full Text] [Related]
11. Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE‑cadherin/EphA2/MMP9/MMP2 expression.
Guo JQ; Zheng QH; Chen H; Chen L; Xu JB; Chen MY; Lu D; Wang ZH; Tong HF; Lin S
Int J Oncol; 2014 Sep; 45(3):1065-72. PubMed ID: 24938458
[TBL] [Abstract][Full Text] [Related]
12. The EphA2 and cancer connection: potential for immune-based interventions.
London M; Gallo E
Mol Biol Rep; 2020 Oct; 47(10):8037-8048. PubMed ID: 32990903
[TBL] [Abstract][Full Text] [Related]
13. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice.
Chen Z; Liu Z; Zhang M; Huang W; Li Z; Wang S; Zhang C; Dong B; Gao J; Shen L
Int J Cancer; 2019 Nov; 145(9):2440-2449. PubMed ID: 30957241
[TBL] [Abstract][Full Text] [Related]
14. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM
J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157
[TBL] [Abstract][Full Text] [Related]
15. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
16. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2004 Aug; 320(4):1096-102. PubMed ID: 15249202
[TBL] [Abstract][Full Text] [Related]
17. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.
Shitara K; Satoh T; Iwasa S; Yamaguchi K; Muro K; Komatsu Y; Nishina T; Esaki T; Hasegawa J; Kakurai Y; Kamiyama E; Nakata T; Nakamura K; Sakaki H; Hyodo I
J Immunother Cancer; 2019 Aug; 7(1):219. PubMed ID: 31412935
[TBL] [Abstract][Full Text] [Related]
19. Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer.
Fujimoto Y; Suehiro Y; Kaino S; Suenaga S; Tsuyama T; Matsui H; Higaki S; Fujii I; Suzuki C; Hoshida T; Matsumoto T; Takami T; Nagano H; Sakaida I; Yamasaki T
Oncology; 2021; 99(4):234-239. PubMed ID: 33440396
[TBL] [Abstract][Full Text] [Related]
20. Cancer-associated fibroblasts promote gastric tumorigenesis through EphA2 activation in a ligand-independent manner.
Hong HN; Won YJ; Shim JH; Kim HJ; Han SH; Kim BS; Kim HS
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1649-1663. PubMed ID: 29948146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
